In patients with T2DM and hypertriglyceridemia, pemafibrate also decreased other lipid components, namely non-HDL and remnant lipoprotein cholesterols, apolipoprotein (Apo) B100, ApoB48, ApoCIII while enhanced insulin sensitivity score, HDL-cholesterols, and ApoA-I levels in the blood circulation [120]. This evidence concerns the gene APOB and hypertriglyceridemia.